The genomic landscape of recurrent pancreatic cancer is modified by treatment

Most patients who undergo curative intent surgery for pancreatic cancer will still die of recurrent disease. A new study shows that pancreatic tumours that pass through the genetic bottlenecks of surgery and additional chemoradiotherapy have altered mutational signatures, driver genes and subclonal architecture.